Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

DenmarkBack to Denmark

Clinical trials in Herlev – page 7

303 clinical trials in Herlev, Denmark across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

DenmarkOur site in DenmarkKliniske-Forsoeg.dk(opens in a new tab)
Herlev at a glance
303
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

303 trials in Herlev

Open in trial search

Ovarian cancer recurrent+1

Recruiting

Study of Sacituzumab Tirumotecan and Bevacizumab for Patients with Recurrent Ovarian Cancer

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Type 2 diabetes mellitus

Recruiting

Study on Using Dapagliflozin, Semaglutide, and Finerenone to Prevent Heart and Kidney Complications in Patients with Type 2 Diabetes

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Steno Diabetes Center Copenhagen

Basal cell carcinoma

Recruiting

Study Comparing Electrochemotherapy with Bleomycin to Standard Radiotherapy for Treating Basal Cell Carcinoma in Patients with Tumors Less Than 3 cm

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Bleomycin
  • Sponsor:Region Hovedstaden

Pancreatic carcinoma metastatic+1

Recruiting

Study of TCR-Modified T Cell Therapy with ANOC-001, ANOC-002, and ANOC-003 for Adults with Advanced Pancreatic Cancer

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:ANOC-001
  • Sponsor:Anocca AB

Intensive care

Recruiting

Evaluation of enoxaparin, dalteparin, nadroparin, tinzaparin and human albumin in adults admitted to intensive care unit with acute critical illness

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Dalteparin Sodium
  • Sponsor:Rigshospitalet

Tubulointerstitial nephritis

Recruiting

Study on Prednisolone for Treating Acute Interstitial Nephritis in Patients

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:Region Midtjylland

Malignant melanoma

Recruiting

Study on [68Ga]Ga-FAPI-46 and Fludeoxyglucose (18F) PET/CT Imaging for Evaluating Treatment Response in Patients with Advanced Malignant Melanoma

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Rigshospitalet

Staphylococcal bacteraemia

Recruiting

Study on the Effectiveness of Clarithromycin and Other Drug Combinations for Patients with Uncomplicated Staphylococcus aureus Blood Infection

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Amikacin
  • Sponsor:Hvidovre Hospital

Hip fracture

Recruiting

Study on the Effects of Ferric Derisomaltose on Mobility in Elderly Patients After Hip Fracture Surgery

Registered drug
Countries:DenmarkDenmark
  • Participants:65+ years
  • Substances:Ferric Derisomaltose
  • Sponsor:Rigshospitalet

Extra-osseous Ewing's sarcoma+5

Recruiting

Study of drug combination therapy for patients with recurrent and primary refractory Ewing Sarcoma

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel
  • Sponsor:The University Of Birmingham

Bacterial infection

Recruiting

Study on Reducing Infections After Bladder Removal Surgery Using Pivmecillinam Hydrochloride and Other Antibiotics for Patients Undergoing Ureteral Stent Removal

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin
  • Sponsor:Rigshospitalet

Bladder transitional cell carcinoma

Recruiting

Study on Mitomycin and BCG for Patients with Recurrent Non-Muscle Invasive Bladder Cancer

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Mitomycin
  • Sponsor:Aarhus University

Other cities in Denmark

The busiest research cities in the country

All 48 cities in Denmark

Clinical research in Herlev

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments, particularly in endometrial, prostate, and bladder cancers. Studies are evaluating novel combination therapies and immunological approaches.

  • Endometrial Cancer Treatment Studies
  • Metastatic Prostate Cancer Therapies
  • Bladder Cancer Interventions

Research aims to improve treatment outcomes and survival rates through targeted therapeutic approaches.

02 Cardiovascular and Metabolic Studies

Comprehensive research into heart failure prevention and treatment of metabolic conditions, including studies on innovative drug combinations and biomarker-targeted approaches.

  • Heart Failure Prevention Trials
  • Diabetes and Kidney Disease Research
  • Obesity Management Studies

Focus on developing preventive strategies and improving patient outcomes in cardiovascular conditions.

03 Preventive Medicine

Studies examining vaccine effectiveness and preventive treatments, particularly in meningococcal and varicella infections. Research includes both pediatric and adult populations.

  • Meningococcal Vaccine Studies
  • Chickenpox Vaccination Research
  • Immunization Response Analysis

Emphasis on developing safe and effective preventive measures for infectious diseases.

Back to DenmarkAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.